Hope Is Rising for Oral Drug for Neurodegenerative Disease Treatments
LONDON – Any signs of neurodegeneration in a mouse model of Alzheimer’s disease can be halted with a compound that can be taken by mouth, a new study has shown. The drug, which was originally developed for another purpose, inhibits a metabolic pathway in the brain called the unfolded protein response (UPR). Normally, the UPR transiently shuts down protein production when abnormal proteins are produced. Because the UPR is thought to be overactive in a range of neurodegenerative diseases, drugs that inhibit it may have the potential to treat those conditions.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter